SCHEMBL3401624

SCHEMBL3401624

Cc1cc(N)ccc1CN1C[C@@H](C)N[C@@H](C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.44
NR1H2 P55055 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
RAD52 P43351 1/20 0.36
GFER P55789 1/20 0.36
ALDH1A1 P00352 2/20 0.36
S1PR1 P21453 1/20 0.36
S1PR5 Q9H228 1/20 0.36
ACHE P22303 3/20 0.36
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401621 1.00 SIGMAR1 (0.44) SIGMAR1NR1H2GAAMAPTRAD52
SCHEMBL3397028 0.88 KMT2A (0.46) SIGMAR1NR1H2ALDH1A1ACHEKDM4E
SCHEMBL3397026 0.88 KMT2A (0.46) SIGMAR1NR1H2ALDH1A1ACHEKDM4E
SCHEMBL9609631 0.76 ACHE (0.60) NR1H2GAAMAPTRAD52GFER
SCHEMBL3396312 0.76 LMNA (0.51) SIGMAR1ALDH1A1CYP3A4
SCHEMBL3396309 0.76 LMNA (0.51) SIGMAR1ALDH1A1CYP3A4
SCHEMBL31203139 0.75 NR1H2 (0.43) NR1H2GAAMAPTRAD52GFER
SCHEMBL31202959 0.75 NR1H2 (0.43) NR1H2GAAMAPTRAD52GFER
SCHEMBL15650085 0.74 SIGMAR1 (0.45) SIGMAR1ALDH1A1MEN1KMT2ATP53
SCHEMBL4937802 0.73 GAA (0.60) NR1H2GAAMAPTRAD52GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101981036-B Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors NOVARTIS AG 2013-09-04 CN disclosed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 EP disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 SIGMAR1 2387/4885NR1H2 3187/4885GAA 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.